Amarin's Vascepa: Too Limited A Market Or FDA Blunder?

Is Amarin's (NASDAQ: AMRN ) Vascepa the victim of its own ineptitude, or the target of an effort by Big Pharma to keep it off the market? Those questions and others have been lobbed around lately by a variety of industry observers and investors, regarding Amarin's sole product, Vascepa –